Ppp6cはマウスメラノーマ発がんにおいて腫瘍抑制因子として機能する

1. Elwood JM, Gallagher RP. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int J cancer. 1998;78:276-280.

2. Ishihara K, Saida T, Yamamoto A. Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol. 2001;6:109-116.

3. Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006;355:51-65.

4. Bakhoum MF, Esmaeli B. Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project. Cancers (Basel). 2019; 11(8):1061.

5. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-63.

6. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006-14.

7. Hammond D, Zeng K, Espert A, et al. Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J Cell Sci. 2013;126(Pt 15):3429-40.

8. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell. 2009;139(3):468-84.

9. Brautigan DL. Protein Ser/Thr phosphatases--the ugly ducklings of cell signalling. FEBS J. 2013;280(2):324-45.

10. Ohama T. The multiple functions of protein phosphatase 6. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):74-82.

11. Mi J, Dziegielewski J, Bolesta E, Brautigan DL, Larner JM. Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6. PLoS ONE. 2009;4(2):e4395.

12. Hosing AS, Valerie NC, Dziegielewski J, Brautigan DL, Larner JM. PP6 regulatory subunit R1 is bidentate anchor for targeting protein phosphatase-6 to DNA-dependent protein kinase. J Biol Chem. 2012;287(12):9230-9.

13. Zeng K, Bastos RN, Barr FA, Gruneberg U. Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2. J Cell Biol. 2010;191(7):1315-32.

14. Ziembik MA, Bender TP, Larner JM, Brautigan DL. Functions of protein phosphatase-6 in NF-kappaB signaling and in lymphocytes. Biochem Soc Trans. 2017;45(3):693-701.

15. Stefansson B, Brautigan DL. Protein phosphatase 6 subunit with conserved Sit4-associated protein domain targets IkappaBepsilon. J Biol Chem. 2006;281(32):22624-34.

16. Kajino T, Ren H, Iemura S, et al. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J Biol Chem. 2006;281(52):39891-6.

17. Zhong J, Liao J, Liu X, Wang P, Liu J, Hou W, et al. Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks. Cell cycle. 2011;10(9):1411-9.

18. Ghasemi M, Samaei NM, Mowla SJ, et al. Upregulation of miR-371-373 cluster, a human embryonic stem cell specific microRNA cluster, in esophageal squamous cell carcinoma. J Cancer Res Ther. 2018;14:S132-S137.

19. Wu N, Liu X, Xu X, et al. MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma. FEBS J. 2011;278(12):2044-54.

20. Hayashi K, Momoi Y, Tanuma N, et al. Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA. Oncogene. 2015;34(35):4647-55.

21. Kato H, Kurosawa K, Inoue Y, et al. Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis. Cancer Lett. 2015;365(2):223-8.

22. Kurosawa K, Inoue Y, Kakugawa Y, et al. Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D-driven tumor promotion. Cancer Sci. 2018;109(7):2178-87.

23. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007;21(4):379–84.

24. Ogoh H, Tanuma N, Matsui Y, Hayakawa N, Inagaki A, Sumiyoshi M, et al. The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesis. Mech Dev. 2016;139:1-9.

25. Soo JK, Ross AD, Bennett DC. Isolation and culture of melanoma and naevus cells and cell lines. Methods Mol Biol. 2011;731:141-50.

26. Rosenthal R, McGranahan N, Herrero J, et al. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;22:17-31.

27. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-6.

28. Hinrichs AS, Karolchik D, Baertsch R, et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res. 2006;1:34.

29. Wang K, Mingyao Li, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.

30. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47(D1):D941-7.

31. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.

32. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-4.

33. Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94-101.

34. Lei WL, Han F, Hu MW, et al. Protein phosphatase 6 is a key factor regulating spermatogenesis. Cell Deat D. 2020;27:1952-1964.

35. Fujiwara N, Shibutani S, Sakai Y, et al. Autophagy regulates levels of tumor suppressor enzyme protein phospatase 6. Cancer Science. 2020;111:4371-4380.

36. Leonard D, Huang W, Izadmehr S, et al. Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell. 2020;181:688-701.

38. Mo X, Zhang H, Preston S, et al. Interferon-g Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. Cancer Res. 2018;78:436-450.

39. Munhoz RR, Postow MA. Clinical development of PD-1/PD-L1 in Advanced Melanoma. Cancer J. 2018;24(1):7-14.

40. Fujimura T, Fujisawa Y, Kambayashi Y, et al. Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers. 2019;11:1342.

41. Subbiah V, Baik C, Kirkwood JM. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer. 2020;6:9.

42. Suganuma M, Fujiki H, Suguri H, et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Nati Acad Sci USA. 1988;85:1768-1771.